Compare Bandwidth Inc (BAND) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bandwidth Inc vs Twist Bioscience Corp — how do they compare? Bandwidth Inc trades at $51.99 (market cap $1.66B), while Twist Bioscience Corp trades at $123.63 (market cap $7.72B). The key difference: Twist Bioscience Corp is far larger — about 4.7× Bandwidth Inc's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Bandwidth Inc nearer its low. Which is the better fit depends on your goals.
| BAND | TWST | |
|---|---|---|
Market Cap | $1.66B | $7.72B |
Sector | Technology | Health |
52-Week High | $78.44 | $124.88 |
52-Week Low | $12.82 | $24.16 |
Enterprise Value | $2.04B | $7.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bandwidth Inc. (BAND) trades at $52.61, down 0.19% today, with a bullish technical trend per moving averages despite overbought RSI signals. Q2 2026 earnings beat expectations with $0.37 EPS, driven by 22% revenue growth and AI-driven communications demand. The company raised its 2026 outlook, highlighting strong enterprise adoption and a record 18.3% adjusted EBITDA margin.
Outlook is positive with 75% analyst buy ratings and a $75.25 consensus price target, but risks include high valuation (EV/EBITDA 34.08) and negative ROE. Earnings growth from AI integration and margin expansion supports upside, though profitability remains thin with a 0.27% net margin projected for 2026.
TWST is trading at $124.88, up 7.96% in the last 24 hours, near its pivot point of $121 with resistance at $129. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Revenue growth is robust, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, but the company remains unprofitable with a net income margin of -31.66% and negative cash flow from operations. Recent news highlights an upsized $300 million public offering and expansion in AI-driven drug discovery.
The outlook for TWST is mixed; bullish analyst sentiment and AI growth potential are offset by persistent losses and high valuation multiples. Investment opportunity lies in sustained revenue expansion and path to profitability, but risks include cash burn, competitive pressures, and execution challenges in scaling operations. The stock's current price exceeds the consensus target of $106.14, suggesting limited near-term upside based on fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bandwidth Inc
Bandwidth is a global communications software company. Its CPaaS platform allows enterprises to embed voice, messaging, and 911 emergency services directly into their software applications via robust APIs.
Read more on BAND →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
